secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001437749-25-001459
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DSMB recommends Vaxart's COVID-19 Phase 2b trial proceed; norovirus Phase 1 in H1 2025
--------------------------------------------------------------------------------

- DSMB recommends Phase 2b proceed after review of 30-day safety data from 400-participant sentinel cohort.
- Trial to enroll ~10,000 participants pending FDA review and BARDA approval.
- Norovirus Phase 1 trial of second-gen vs first-gen constructs to start H1 2025, topline data mid-2025.
- New avian influenza vaccine candidate (clade 2.3.4.4b) in preclinical studies.
- Cash runway into 2026 supported by BARDA award of up to $460.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925001459/0001437749-25-001459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925001459/vxrt20250120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer